NovaBay Pharmaceuticals Inc.
10/22/2025 | Press release | Distributed by Public on 10/22/2025 14:09
Material Event (Form 8-K)
Item 8.01. Other Information.
As previously disclosed in the Current Report on Form 8-K filed by NovaBay Pharmaceuticals, Inc. (the "Company") on October 20, 2025, the Company filed the certificate of designation of preferences, rights and limitations of Series E Non-Voting Convertible Preferred Stock, par value $0.01 per share (the "Certificate of Designation for the Series E Preferred Stock") with the Delaware Secretary of State on October 16, 2025. The Certificate of Designation for the Series E Preferred Stock is filed as Exhibit 3.1 to this Current Report on Form 8-K.
NovaBay Pharmaceuticals Inc. published this content on October 22, 2025, and is solely responsible for the information contained herein. Distributed via EDGAR on October 22, 2025 at 20:09 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]